Loading
AV-1980R 60 µg / Alzheimer Disease / AV-1980R 180 µg · Phase 1 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 clinical trial registration for AV-1980R, a novel tau-targeting vaccine in preclinical Alzheimer's disease. No results are reported in this registry record; the trial is currently recruiting and designed to evaluate safety, tolerability, and immunogenicity through Week 58.
Phase 1, Interventional, Randomized, Parallel, Quadruple masking, Prevention purpose. Alzheimer Disease, Preclinical Alzheimer's Disease; age from 65 Years; to 80 Years. Intervention: AV-1980R 20 µg Arm; AV-1980R 60 µg Arm; AV-1980R 180 µg Arm. Compared with: Placebo Arm — Placebo Comparator. n = 48. 6 sites: United States.
This is a Phase 1 clinical trial registration for AV-1980R, a novel tau-targeting vaccine in preclinical Alzheimer's disease. No results are reported in this registry record; the trial is currently recruiting and designed to evaluate safety, tolerability, and immunogenicity through Week 58.
Phase 1 design focuses on safety and immunogenicity; no cognitive or clinical efficacy endpoints are specified.
This early-phase trial cannot yet inform clinical practice. Results when available will provide initial safety and immunogenicity signals for AV-1980R in asymptomatic individuals at risk for cognitive decline; efficacy data would be needed before any clinical recommendation.
Phase 1 trial of a novel tau vaccine in preclinical AD; no results reported in this registry record, and the primary focus is safety and tolerability rather than clinical efficacy.
As stated by the source record.
Quoted from the source exactly as published.
This early-phase trial cannot yet inform clinical practice. Results when available will provide initial safety and immunogenicity signals for AV-1980R in asymptomatic individuals at risk for cognitive decline; efficacy data would be needed before any clinical recommendation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07158905). This is a study registration, not published results. Lead sponsor: Institute for Molecular Medicine. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 48 participants (ESTIMATED). Conditions: Alzheimer Disease, Preclinical Alzheimer's Disease. Interventions: BIOLOGICAL: AV-1980R 20 µg; BIOLOGICAL: AV-1980R 60 µg; BIOLOGICAL: AV-1980R 180 µg; OTHER: Placebo. Primary outcome measures: Number of Participants with Treatment-Emergent Adverse Events and Serious Adverse Events , Baseline through Week 58. Brief summary: This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological tau, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65 to 80 years with biomarker evidence of preclinical Alzheimer's disease will be enrolled into three ascending-dose cohorts.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.